BARDA

The Biomedical Advanced Research and Development Authority (BARDA) has issued a Sources Sought Notice titled “Advanced Dermal Regeneration Substitutes for Treatment of Severe Burns and Complex Traumatic Injuries” (BARDA-CBRN-07282026) to identify commercially available or near commercial technologies that address large-area skin loss from burns and traumatic injuries in a mass casualty setting. This notice is for […]

Overview of the Opportunity The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), has released a new Request for Information (RFI) titled “Biosafety Level 4 Preclinical and Nonclinical Support for Medical Countermeasure Development (BSL4)”. Issued July 9, 2026, the RFI is a market research exercise to map out who can deliver preclinical and nonclinical

Download the Solicitation Overview of the RFI The Biomedical Advanced Research and Development Authority (BARDA) is looking at a specific problem: how to repurpose specialized equipment originally designed to manufacture an emergency autoinjector platform into a broader drug delivery solution. Through the Rapid Response Partnership Vehicle (RRPV), BARDA released a new Request for Information (RFI), “Repurposing Equipment

Download the Solicitation Overview of the RFI The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), has released a Request for Information (RFI) titled “Advanced Clinical Development and Licensure of an Adjuvanted Egg-based Influenza Vaccine.” Through this market research effort, BARDA is seeking feedback from industry, academia, and other stakeholders to

Download the Solicitation Overview of the RFI The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), has released a Request for Information (RFI) titled “High Performance Antigen Diagnostics.” Through this market research effort, BARDA is seeking feedback from industry, academia, and other stakeholders to better understand the landscape of current and emerging high-performance immunoassay

Download the Solicitation The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), has officially released Request for Project Proposals (RPP) RRPV 26-13-BundiVx for the Bundibugyo Virus Outbreak Response Vaccines (BundiVx) Program. The solicitation seeks to accelerate the development of investigational vaccine candidates targeting Bundibugyo ebolavirus (BDBV), the virus responsible for

Download the RFI Overview of the RFI The Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response (ASPR), has released a Request for Information (RFI) titled “Protection Before Day One Vaccine: Advancing Broadly Protective Seasonal Influenza Vaccines with Pandemic Coverage.” Through this market research effort, BARDA is seeking feedback from industry, academia, and

Download the Solicitation The Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), has issued a Request for Information (RFI) to better understand the current development landscape for antifungal medical countermeasures. BARDA plays a central role in advancing

Download the Solicitation The Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), has issued a Request for Information (RFI) focused on AI-Enabled Discovery of Broad-Spectrum Small-Molecule Inhibitors for Filoviruses. Filoviruses, including Ebola virus (EBOV), Sudan virus

BARDA_FY23 Modernized BAA Solicitation – Amendment 7 The Biomedical Advanced Research and Development Authority (BARDA) has released its modernized Broad Agency Announcement (BAA-23-100-SOL-00004, Amendment 7), creating a flexible, multi-year pathway for industry to partner with the U.S. Government on advanced medical countermeasures (MCMs) for CBRN, pandemic influenza, and emerging infectious disease threats to the U.S.